Evidence map›Paper›PMID 42559701›Full record

ArticleNeuropsychopharmacology reports2026

Possible Contribution of Multiple Sclerosis Pathology to Treatment-Resistant Schizophrenia: A Case Study.

Sho Miura, Atsuko Nagaoka, Mizuki Hino, Risa Shishido, Masataka Hatano, Yuto Hosogai, Kazusa Miyahara, Yuta Oba, Kimihiko Kaneko, Yasuto Kunii and 1 more

Abstract readCase Reports
In one paragraph

Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sho MiuraDepartment of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.ORCID https://orcid.org/0009-0006-2029-2241
Atsuko NagaokaDepartment of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0002-1159-4436
Mizuki HinoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.ORCID https://orcid.org/0000-0003-3700-0322
Risa ShishidoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.ORCID https://orcid.org/0000-0002-7860-0036
Masataka HatanoDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yuto HosogaiDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kazusa MiyaharaDepartment of Disaster Psychiatry, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan.ORCID https://orcid.org/0009-0003-9751-0786
Yuta ObaDepartment of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.
Kimihiko KanekoDepartment of Neurology, Tohoku University Hospital, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0001-8469-9338
Yasuto KuniiDepartment of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.ORCID https://orcid.org/0000-0003-1569-7819
Hiroaki TomitaDepartment of Psychiatry, Tohoku University Hospital, Sendai, Miyagi, Japan.

Funding

Japan Agency for Medical Research and Development JP25wm0625126Japan Society for the Promotion of Science 24K02376Japan Society for the Promotion of Science 24K18734Japan Society for the Promotion of Science 25K19063Niigata University 25009
6 · The paper itself

Abstract

Multiple sclerosis (MS) can present with neurological and psychiatric symptoms that may overlap with those of schizophrenia, making differentiation difficult particularly because their typical onset ages are similar. We present the case of a woman in her 50s who developed persecutory delusions and a subjective sense of being under surveillance in Year X-31 and was diagnosed with schizophrenia. Despite the long-term antipsychotic treatment, the patient's symptoms persisted and worsened. In Year X-1, brain magnetic resonance imaging revealed multiple white matter lesions, and then cerebrospinal fluid analysis revealed oligoclonal bands, leading to a diagnosis of MS. Treatment with ofatumumab was initiated. Owing to persistent psychiatric symptoms, clozapine was administered, which showed partial effectiveness. This case highlights the clinical overlap between schizophrenia and MS and suggests that comorbid MS pathology may be clinically relevant in the context of treatment resistance and cognitive impairment. Similarities in symptoms and disease course raise the possibility that a subset of patients with schizophrenia may share pathophysiological features with MS. In addition, postmortem studies, including our previous and current observations, provide hypothesis-generating support for partially overlapping MS-like changes in some patients with schizophrenia. Clinicians should consider the possibility of comorbid MS in patients with treatment-resistant schizophrenia, particularly when atypical clinical or neurological features are present.

Indexed as

Multiple SclerosisSchizophreniaSchizophrenia, Treatment-ResistantAntipsychotic AgentsFemaleHumansMiddle AgedAntipsychotic Agentsmultiple sclerosispsychosistreatment‐resistant schizophrenia

Identifiers

PMID42559701
PMCPMC13445245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.